# Imago BioSciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imago-biosciences

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.imagobio.com
- Total disclosed funding: $106M
- Latest round: Series C (Nov 12, 2020)
- Investors on record: 18

## About

Founded in 2012 and based in California, US, Imago BioSciences, Inc. operates as a biopharmaceutical company that develops various therapeutical solutions for the treatment of bone marrow diseases and hematologic disorders targeting epigenetic enzymes. The company was founded by its CEO Hugh Rienhoff. Imago BioSciences has raised a total of USD 146.5 million in funding over 3 rounds from 17 investors including The Blackstone Group Inc, Omega Funds, MRL Ventures and Farallon Capital Management. In November 2020, Imago BioSciences, Inc. received its latest series C funding from a group of investors that includes Amgen Ventures, BlackRock Advisors, and Blackstone Group. The company released its IPO on NASDAQ in July 2015 under the ticker symbol IMGO.

The company's product consists of therapeutical solutions that focus on the treatment of thrombocythemia, myelofibrosis, other myeloproliferative neoplasms, bone marrow diseases, and hematologic disorders. It offers Bomedemstat, an orally available LSD1 inhibitor solution that provides treatment for myeloproliferative neoplasms (MPNs) which are related to chronic cancers of the bone marrow, polycythemia vera (PV), and acute myeloid leukemia (AML). The company also offers treatments for conditions that involve Hemoglobinopathies and other solid tumors caused by LSD1 or lysine-specific demethylase 1.

The company's revenue is generated by the sales of its therapeutic solutions to patients with conditions such as thrombocythemia, myelofibrosis, other myeloproliferative neoplasms, bone marrow diseases, and hematologic disorders.

The company plans to widen the scope of its therapeutic solution by enrolling patients with an MPN known as essential thrombocythemia in Phase 2 clinical trials. As of July 2021, Imago BioSciences, Inc. also plans to become a publicly listed company under the ticker symbol IMGO on the Nasdaq.

## Funding rounds

- Series C, Nov 12, 2020, $80M — Blackstone Group, Frazier Healthcare Partners, T Rowe Price, Greenspring Associates, Amgen Ventures, Kingdon Capital Management, Surveyor Capital, Omega Funds, BlackRock, Pharmaron Beijing Co., Ltd., Farallon Capital Management, Xeraya Capital, HighLight Capital, MRL Ventures Fund, Irving Investors
- Series B, Mar 15, 2019, $17M — Frazier Healthcare Partners, Greenspring Associates, Amgen Ventures, Omega Funds, Pharmaron Beijing Co., Ltd., HighLight Capital, MRL Ventures Fund
- Series A, Oct 31, 2014, $8.8M — Amgen Ventures, Clarus Ventures, Merck Global Health Innovation Fund, Frazier Healthcare

## Investors

- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series A, Series B, Series C
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series A
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series A
- Frazier Healthcare — Series A
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series B, Series C
- Greenspring Associates (https://capitalatlas.ai/funds/greenspring-associates) — Series B, Series C
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B, Series C
- Pharmaron Beijing Co., Ltd. — Series B, Series C
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B, Series C
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series B, Series C
- Blackstone Group (https://capitalatlas.ai/funds/blackstone-group) — Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C
- Kingdon Capital Management — Series C
- Surveyor Capital — Series C
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series C
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series C
- Xeraya Capital (https://capitalatlas.ai/funds/xeraya-capital) — Series C
- Irving Investors (https://capitalatlas.ai/funds/irving-investors) — Series C